We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Compact Proton Therapy System Provides Advanced Beam Modes

By MedImaging International staff writers
Posted on 31 Aug 2016
Print article
Image: The IBA Proteus ONE IMPT system (Photo courtesy of IBA).
Image: The IBA Proteus ONE IMPT system (Photo courtesy of IBA).
A new intensity modulated proton therapy (IMPT) system allows clinicians to operate with sub-millimetric precision treatment.

The IBA Proteus ONE is a single-room configuration consisting of an accelerator, a direct beam line, and a compact gantry. The smaller footprint of the Proteus ONE allows for correspondingly smaller facilities, reducing construction and maintenance costs, which helps make the technology available to more cancer care providers. It also reduces the amount of time staff members need to position patients for optimal treatment, which helps reduce treatment times and patient stress.

The Proteus ONE is equipped with pencil beam scanning (PBS) which allows delivery of very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue. Advanced imaging techniques include cone beam computed tomography (CBCT) and stereoscopic imaging, which allow the treatment of a diverse range of ocular tumors, central nervous system (CNS) tumors, head and neck malignancies, thoracic malignancies, and abdominal and pelvic malignancies.

The compact gantry offers a rolling floor design for 360° of treatment access. This is achieved due to the 220° rotating structure and a robotic patient positioner with the six degrees of freedom of movement. And since the system is allocated with a dedicated accelerator, the need for a control space and the accompanying operational requisites are eliminated. The Proteus ONE IMPT system is a product of Ion Beam Applications (IBA; Louvain-La-Neuve, Belgium), and has been approved by the U.S. Food and Drug Administration (FDA).

“The Proteus ONE aligns with the US healthcare trend of providing the highest quality of cancer treatment possible at the best possible price,” said Olivier Legrain, CEO of IBA commented: “We are confident that Proteus ONE will drive greater momentum in the adoption of this next generation targeted cancer treatment internationally. The approval reaffirms our world leading position in the delivery of highly targeted, safer cancer treatment solutions.”

Proton therapy is a precise form of radiotherapy (RT) that uses charged particles instead of x-rays. It can be a more effective form of treatment than conventional RT as it directs the therapeutical radiation beam more precisely, with minimal damage to surrounding tissue. Evidence is growing that protons can be effective in treating a number of cancers, in particular children and young people with brain tumors, for whom it appears to produce fewer side effects such as secondary cancers, growth deformity, hearing loss, and learning difficulties.

Related Links:
Ion Beam Applications

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
PACS Workstation
CHILI Web Viewer
Thyroid Shield
Standard Thyroid Shield
New
1.5T MRI System
uMR 670

Print article

Channels

Ultrasound

view channel
Image: Microscopic heart vessels have been imaged in super-resolution for the first time (Photo courtesy of Imperial College)

Super-Resolution Imaging Technique Could Improve Evaluation of Cardiac Conditions

The heart depends on efficient blood circulation to pump blood throughout the body, delivering oxygen to tissues and removing carbon dioxide and waste. Yet, when heart vessels are damaged, it can disrupt... Read more

Nuclear Medicine

view channel
Image: Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration (Photo courtesy of SNMMI)

New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients

Clear cell renal cell cancer (ccRCC) represents 70-80% of renal cell carcinoma cases. While localized disease can be effectively treated with surgery and ablative therapies, one-third of patients either... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more